Is There Hope for Sarepta?

An FDA decision another drug maker’s Duchenne muscular dystrophy therapy is spelling bad news for Sarepta Therapeutics ( SRPT ).
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.